PharmaTelevision Interview to Spotlight Aptalis Pharma President John Fraher
Company strategy, portfolio development and emerging markets are just a few of the topics that John Fraher, president of Aptalis Pharma, is scheduled to address during an on-air interview with Fintan Walton, CEO, PharmaVentures and PharmaTelevision. The interview is available via on-demand at PharmaTelevision beginning Monday 22 August and will remain available to the public long-term.
As Aptalis Pharma’s president, Fraher serves a key role in setting strategic direction for Aptalis, with specific oversight of the company’s Pharmaceutical Technologies and Global Supply Chain business unit. PharmaTelevision is an online TV channel for the biopharma industry offering feature interviews with industry leaders, analysis and a television news archive.
Fraher will discuss the Aptalis experience. In February 2011, Axcan Intermediate Holdings completed its acquisition of Eurand and on 4 May, the two companies announced their combined name as Aptalis. Aptalis is a specialty pharmaceutical company that provides innovative, effective therapies for unmet medical needs, including cystic fibrosis and gastrointestinal disorders.
Aptalis currently markets pharmaceutical products around the world, including ZENPEP®, CANASA®, CARAFATE®, PYLERA®, LACTEOL®, DELURSAN®, and SALOFALK®, and has several compounds in various stages of development, including AEROQUIN® in Phase 3 clinical trials for the treatment of pulmonary infections in patients with cystic fibrosis.
Aptalis Pharmaceutical Technologies, formerly known as Eurand Pharmaceutical Technologies, offers a broad portfolio of oral drug delivery technology platforms: customized drug release, bioavailability enhancement, and taste masking for ODTs (orally disintegrating tablets) and other dosage forms. Together, these technology platforms combined with licensing, manufacturing, and R&D capabilities enable Aptalis Pharmaceutical Technologies to produce customized drug formulation solutions for partners across a range of dosage forms and therapies with high patient acceptability.
Aptalis Pharmaceutical Technologies will continue to develop and manufacture products for its partners, as well as support the drug development process for the Aptalis Pharma pipeline and portfolio of products. For more information about Aptalis Pharmaceutical Technologies, please visit the company’s website.